

CURRICULUM VITAE

August 2007

NAME: Paul S. Jellinger, M.D., M.A.C.E.
DATE OF BIRTH: June 17, 1941
BIRTHPLACE: New York City

PRESENT BUSINESS ADDRESS:

The Center for Diabetes & Endocrine Care
1150 North 35th Avenue
Suite 590
Hollywood, Florida 33021
(954)-963-7100

PREVIOUS BUSINESS ADDRESS:

3700 Washington Street
Suite 305
Hollywood, Florida 33021
(954)-963-7100

PRE-PROFESSIONAL EDUCATION:

1. Horace Mann School
New York, N.Y. 1956-1959
2. Hobart College
Geneva, New York B.A. 1959-1964
3. Graduate Division 1964-1965
City College of New York
Masters Program in Biology
New York City, N.Y.

PROFESSIONAL EDUCATION:

1. Wayne State University
School of Medicine
Detroit, Michigan M.D. 1965-1969

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 2

POST-GRADUATE TRAINING:

1. Fellowship - Endocrinology (N.I.H. Fellow)
The Mount Sinai Hospital
New York City, N.Y. 1973-1974
2. Fellowship - Endocrinology
The Mount Sinai Hospital -- (Bronx V.A. Affiliation)
New York, N.Y. 1972-1973
3. Second Year Residency - Internal Medicine
The Mount Sinai Hospital
New York City, N.Y. 1971-1972
4. First Year Residency - Internal Medicine
Beth Israel Hospital
New York City, N.Y. 1970-1971
5. Internship - Straight Medicine
Beth Israel Hospital
New York City, N.Y. 1969-1970

SPECIALTY CERTIFICATION & LICENSURE:

1. American Board of Internal Medicine
Sub-Specialty Board in Endocrinology & Metabolism
Certified, October 1975
2. American Board of Internal Medicine
Certified, June 1972
3. State of Florida License #22389
Issued June, 1974
4. New York State License #106101
Issued June, 1970
5. Diplomate,
National Board of Medical Examiners - 1970

ACADEMIC APPOINTMENTS:

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 3

1. Professor of Medicine
Voluntary Faculty
University of Miami School of Medicine
Miami, Florida 2000 -
2. Clinical Professor
Department of Medicine (Endocrinology)
University of Miami School of Medicine
Miami, Florida 1995 - 2000
3. Clinical Associate Professor
Department of Medicine (Endocrinology)
University of Miami School of Medicine
Miami, Florida 1984-1995
4. Clinical Assistant Professor
Department of Medicine (Endocrinology)
University of Miami School of Medicine
Miami, Florida 1975-1984
5. Director, Endocrine & Diabetes Clinic
Jackson Memorial Hospital
University of Miami School of Medicine
Miami, Florida 1975-1977
6. Consulting Physician in Medicine (Endocrinology)
V.A. Hospital
Miami, Florida 1975-
7. Clinical Instructor
Department of Medicine (Endocrinology)
University of Miami School of Medicine
Miami, Florida 1974-1975
8. Assistant
Department of Medicine
The Mt. Sinai School of Medicine
New York City, N.Y. 1971-1972

HOSPITAL APPOINTMENTS:

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 4

1. Chief, Section of Endocrinology
Memorial Regional Hospital -- Hollywood, FL 1993-1996
2. Senior Attending Staff
Memorial Regional Hospital—Hollywood, FL 1974-
3. Attending Staff
Hollywood Medical Center—Hollywood, FL 1974-1998
4. Attending Staff
Jackson Memorial Hospital
University of Miami School of Medicine—Miami, FL 1975-1982
5. Director, Endocrine & Diabetes Clinic
Jackson Memorial Hospital
University of Miami School of Medicine—Miami, FL 1975-1976
6. Consulting Staff
Biscayne Medical Center—Miami, FL 1975-1976

PUBLICATIONS:

1. ACE/AACE DIABETES ROADMAPS TO ACHIEVE GLYCEMIC GOALS:
CO-CHAIRMAN, ACE/AACE ROADMAP TASK FORCE
Endocrine Practice, 2007, Vol. 13, No.3 May/June 2007, p.260- 268.
2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
(AACE) DIABETES MELLITUS CLINICAL PRACTICE GUIDELINES
TASK FORCE
Endocrine Practice, Vol. 13, (Suppl 1) May/June 2007
3. ACE/AACE CONSENSUS CONFERENCE ON THE IMPLEMENTATION
OF OUTPATIENT MANAGEMENT OF DIABETES MELLITUS:
CONSENSUS CONFERENCE RECOMMENDATIONS
Endocrine Practice, Vol. 12, No. 1 Jan/Feb 2006, p. 6-12
4. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
POSITION STATEMENT ON METABOLIC AND CARDIOVASCULAR
CONSEQUENCES OF POLYCYSTIC OVARY SYNDROME
Endocrine Practice, Vol. 11, No. 2 Mar/Apr 2005 p. 125-134
5. ACQUIRED HYPOTHYROIDISM AFTER SWITCHING FROM THYROID
USP TO LEVOTHYROXINE
Clin Cornerstone. 2005;7 Suppl 2:S22-4

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 5

PUBLICATIONS (Continued):

6. AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON INSULIN RESISTANCE SYNDROME
Endocrine Practice Vol. 9 No. 3, May/June 2003 p. 241-251
7. EMERGING CONCEPTS IN MANAGEMENT OF THE INSULIN RESISTANCE SYNDROME
Endocrine Practice, Vol. 9, Supplement 2, Sept/Oct. 2003, p.105-112
8. AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS STATEMENT ON GUIDELINES FOR GLYCEMIC CONTROL
Endocrine Practice, Vol. 8, Supplement 1, Jan/Feb 2002, p.5-11
9. RECOGNIZING CARDIOVASCULAR RISK IN PATIENTS WITH DIABETES
The American Journal of Cardiology
Continuing Education Series Monograph, 2002Editor
10. POSTPRANDIAL HYPERGLYCEMIA AND CARDIOVASCULAR RISK
The American Journal of Cardiology
Continuing Education Series Monograph, 2002, p.11-15
11. A.A.C.E. MEDICAL GUIDELINES FOR THE TREATMENT OF DYSLIPIDEMIA IN THE PREVENTION OF ATHEROGENESIS
Chairman, Task Force
American Association of Clinical Endocrinologists,
Endocrine Practice, Vol. 6, p. 162 –213, 2000
12. A.A.C.E. GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS,
Task Force
American Association of Clinical
Endocrinologists, Revised, 2000
13. A.A.C.E. GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS,
Task Force
American Association of Clinical Endocrinologists, 1994
14. A.A.C.E. CLINICAL PRACTICE GUIDELINES FOR THE EVALUATION AND TREATMENT OF HYPERTHYROIDISM AND HYPOTHYROIDISM,
Task Force
American Association of Clinical Endocrinologists, 1994.

PUBLICATIONS (Continued):

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 6

15. LH RESPONSIVENESS IN SUBJECTS WITH SECONDARY AMENORRHEA: Clinical Research (abstra.), Vol. XXIII, No. 3, April, 1975

ORGANIZATIONS:

1. Broward County Medical Association
2. Florida Medical Association
3. American Medical Association
4. American Diabetes Association
5. The Endocrine Society
6. American Association of Clinical Endocrinologists
7. South Florida Endocrine Association
8. The Florida Endocrine Society
9. American Heart Association

POSITIONS HELD:

1. Immediate Past President
American College of Endocrinology
May 2005 – May 2006
2. Medical Editor
Clinical Endocrinology News, Elsevier Publications
January 2006 -
3. President
American College of Endocrinology
May 2004 – May 2005
4. President-Elect
American College of Endocrinology
May 2003 – May 2004
5. President
American Association of Clinical Endocrinologists
May 2000 - May 2001
5. President Elect
American Association of Clinical Endocrinologist
May 1999 – May 2000
6. Vice-President
American Association of Clinical Endocrinologists
May 1998 - May 1999

POSITIONS HELD (Continued):

7. Treasurer

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 7

- American Association of Clinical Endocrinologists
May 1997 - May 1998
8. Secretary
American Association of Clinical Endocrinologists
May 1996 - May 1997
 9. Program Co-Chairman, Annual Meeting
American Association of Clinical Endocrinologists
San Diego, 1999
 10. Executive Committee
American Association of Clinical Endocrinologists
May, 1996 -
 11. Program Co-Chairman, Annual Meeting
American Association of Clinical Endocrinologists
Chicago, 1995
 12. Chairman, Internet Committee
American Association of Clinical Endocrinologists
1998 -
 13. Program Chairman AACE Clinical Symposium
Dyslipidemia, Diabetes & Obesity
Montreal, August 1997
 14. Program Chairman, American Diabetes Association Council
on Endocrinology; Diabetes and Metabolism,
"The DCCT: One Year Later." New Orleans 1993-1994
 15. Secretary, American Diabetes Association Council on
Endocrinology; Diabetes and Metabolism 1992-1993
 16. Chairman, State Affiliate Organization Committee,
American Association of Clinical Endocrinologists 1994-
 17. Chairman, Clinical MiniFellowship Program Committee
American Association of Clinical Endocrinologists 1994-
 18. Board of Directors
American Association of Clinical Endocrinologists 1992-
- POSITIONS HELD (Continued):**
19. Chairman, Membership Committee
American Association of Clinical Endocrinologists 1991- 1999

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 8

20. Member, Committee on Clinical Practice and Technology
American Association of Clinical Endocrinologists 1991-94
21. Founding Member, Steering Committee
American Association of Clinical Endocrinologists 1991
22. Director, Diabetes Care Unit
Hollywood Medical Center 1987-1992
23. Founder
South Florida Endocrine Association 1988
23. President
Florida Endocrine Society 1986-1988
24. President-Elect
Florida Endocrine Society 1984-1986
25. Secretary/Treasurer
Florida Endocrine Society 1982-1984
26. Director, Endocrine & Diabetes Clinic
Jackson Memorial Hospital
University of Miami School of Medicine—Miami, FL 1975-1977

PROFESSIONAL SOCIETIES:

1. Master, American College of Endocrinology (M.A.C.E.)
2. The Endocrine Society (elected) 1985
3. South Florida Endocrine Association-Founder, 1988
4. The Florida Endocrine Society
5. American Association of Clinical Endocrinologists
6. American Diabetes Association
7. American Heart Association
8. American Heart Association Council on Arteriosclerosis
9. Fellow, American College of Endocrinology (F.A.C.E.)

LECTURE, CONFERENCE & SEMINAR PRESENTATIONS:

Medical Grand Rounds Presentations

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 9

Memorial Hospital, Hollywood, FL

1974-1994

TOPICS

Thyroid Function Tests: An Update

Hypoglycemia

The Thyroid Nodule

Pituitary Disease: New Concepts

Hypercalcemia

Paget's Disease

Osteoporosis

Diabetes Mellitus - 1988 - An Update

Hyperlipidemia - NCME Video Tape-Moderator

Type II Diabetes, New Concepts-Moderator

Diabetes Complications and Control Trial:

A Landmark Study, November, 1993

HONORS:

1. President, American College of Endocrinology, May, 2004 – May 2005
2. Master, American College of Endocrinology, May, 2004
3. President, American Association of Clinical Endocrinologists, May, 2000-May 2001.
4. *Best Doctors in the United States*, 2003-2004, as chosen by peers.
5. *Best Doctors in the United States*, 2001-2002, as chosen by peers.
6. *Best Doctors in the United States*, 2000, as chosen by peers
7. *Best Doctors in Florida*, 2000, as chosen by peers.
8. *Best Doctors in the Southeast United States*, 1999, as chosen by peers.
9. *Best Doctors in South Florida*, 1998, 2000, as chosen by peers.
10. Fellow, American College of Endocrinology,
First Convocation and Assembly, May, 1994.

LOCAL REGIONAL & NATIONAL PRESENTATIONS:

1. Juvenile Diabetes Research Foundation, Miami, FL 1975
Topic: Concepts in Diabetic Control

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 10

2. Nursing Education, Memorial Regional Hospital—Hollywood, FL 1975-1979,
(Yearly)
Topic: Endocrine Emergencies
3. Clinical Radioassay Society, Annual Meeting, Panel Moderator, 1980
Topic: Thyroid Nodules and Neoplasms
4. Florida Osteopathic Medical Association, Annual Meeting, March 1990
Topic: Thyroid Nodules and Neoplasms
5. American Society of Medical Technologists, Annual Meeting,
Florida Division, 1981
Topic: Pituitary Disease: New Concepts & Testing
6. Symposium, Memorial Regional Hospital—Hollywood, FL
Topic: The Dynamics of Calcium Metabolism with Drs. L. Deftos and A.
Norman
7. Florida Endocrine Society, Program Chairman & Moderator, May 1981
Topic: Thyroid Nodule & Neoplasm
8. University of Miami, Sponsored Course in Endocrinology for the
Primary Care Physician, October 1981
Topic: Thyroid Nodule & Neoplasm
9. Diabetes Mellitus, Type II - New Concepts
Roerig Speaker's Board, Pembroke Pines Hospital, March 1989
10. The Significance of HDL Cholesterol in the Hyperlipidemic State
Parke Davis Speaker's Bureau, North Broward Regional Hospital,
Pompano Beach, FL January 1990
11. Hyperlipidemia 1990: An Update - The Role of HDL Cholesterol
Parke Davis Speaker's Bureau, West Palm Beach, FL June 1990
12. Update on Hyperlipidemia - 1990 - The Role of HDL Cholesterol
Parke Davis Speaker's Bureau, Jacksonville, FL April 1990
13. Diseases of the Pituitary Gland
Lecturer in Endocrinology, annually, (Second Year Medical Students)
Southeastern University of Health Sciences, N. Miami Beach, FL July 1990
14. The Significance of HDL Cholesterol in the Hyperlipidemic State
Parke Davis Speaker's Bureau, Orlando, FL February 1991
15. Comparative Pharmacology of Agents Affecting Hypercholesterolemia
Merck, Sharp & Dohme Speaker's Bureau, Orlando, FL May 29, 1991
16. Comparative Pharmacology of Agents Affecting Hypercholesterolemia
Merck, Sharp & Dohme Speaker's Bureau, Ft Lauderdale, FL March 1992
17. Update on Hyperlipidemia
Merck, Sharp & Dohme Speaker's Bureau, Ft Lauderdale, FL Nov. 1992
18. Florida Endocrine Society Annual Meeting 1976 - present
Case presentations and discussion

LOCAL, REGIONAL & NATIONAL PRESENTATIONS (Continued):

19. Diabetic Neuropathy: Clinical Considerations
American Association of Clinical Endocrinologists, Annual Meeting
San Francisco, CA April, 1993 - Workshop Leader
20. Diabetes Complications and Control Trial

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 11

- Memorial Regional Hospital—Hollywood, FL November 1993
21. Diabetes Complications and Control Trial - A Landmark Study
Pratt Pharmaceutical Speaker's Bureau, Hollywood, FL February 1994
 22. Advanced Insulin Infusion Pump Symposium
MiniMed Corporation, Ft Lauderdale, FL March 5th & 6th, 1994
Symposium Moderator & Workshop Leader
 23. Dyslipidemia: When to Treat, Who to Treat & How to Treat
American Association of Clinical Endocrinologists, Annual Meeting
New Orleans, Louisiana, April 1994, Workshop Moderator and Discussant
 24. Diabetes Complications and Control Trial: One Year Later
Council on Endocrinology, Diabetes and Metabolism, American Diabetes
Association Annual Meeting, Program Chairman and Moderator
New Orleans, Louisiana, June 1994
 25. Hyperlipidemia: Treatment and Regression
Merck, Sharp & Dohme Speaker's Bureau, Ft Lauderdale, FL June 1994
 26. Diabetes Complications and Control Trial Results; Implications for Patients with
Type II Diabetes, Sponsored by Novo Nordisk and Boehringer Mannheim Corp
Holy Cross Hospital, Department of Medicine, Ft Lauderdale, FL July 1994
 27. Atherosclerosis for the Endocrinologist: Lipids, Diabetes and Vascular Medicine
American Association of Clinical Endocrinologists Regional Symposium
Program Chairman and Discussant, Palm Beach, FL December 1994
 28. A Practical Approach to the Treatment of Diabetic Neuropathy
American Association of Clinical Endocrinologists Regional Symposium
Keystone, CO January 1995
 29. Method of Implementing Diabetes Intensive Self-Management in NIDDM
American Association of Clinical Endocrinologists
Regional Symposium, Keystone, CO January 1995
 30. Dyslipidemia: Case Studies
American Association of Clinical Endocrinologists, Annual Meeting, Workshop
Leader, Chicago, IL April 1995
 31. Diabetes Grand Rounds: Case Reviews
American Association of Clinical Endocrinologists, Annual Meeting
Moderator & Discussant, Chicago, IL April 1995
 32. NIDDM: Newer Concepts in Diabetic Management
92nd Annual Florida Osteopathic Medical Convention
Doral Ocean Beach Resort, Miami Beach, FL March 1995
 33. New Developments in the Treatment of Type II Diabetes Mellitus
Department of Internal Medicine, North Broward Medical Center
Pompano Beach, FL March 1995
- LOCAL, REGIONAL & NATIONAL PRESENTATIONS (Continued):**
34. New Concepts in Treatment of Type II Diabetes
American Association of Diabetes Educators, South Florida Chapter
Holy Cross Hospital, Ft Lauderdale, FL April 11, 1995
 35. Lipid Disorders and Cardiovascular Disease in Women
Cleveland Clinic Symposium: Women's Health Issues, Ft Lauderdale, FL June 1995
 36. New Developments in the Treatment of Type II Diabetes

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 12

- Memorial Regional/Pembroke Pines Hospital Medical Staff,
Pembroke Pines, FL June 1995.
37. New Developments in the Treatment of Type II Diabetes
Coral Springs Hospital, Department of Internal Medicine/FP
Coral Springs, FL June 1995
 38. Case Studies in Intensive Self Management of Diabetes: Risk Factor Management
AAACE Symposium -- Keystone, CO January 1996
 39. Lipid Disease - Program Moderator
AAACE Annual Meeting -- Seattle, WA May 1996
 40. Lipid Disease - Workshop Leader
AAACE Annual Meeting -- Seattle, WA May 1996

PREVIOUS RESEARCH PROJECTS:

1. An Open Label Study of Fluvastatin in the Treatment of Patients with Hypercholesterolemia In Clinical Practice Settings
Sandoz Pharmaceuticals -- Principal Investigator
2. A Randomized, Multicenter Long-Term Follow-up Trial in Patients with Diabetic Foot Ulcers
Telios Pharmaceuticals Inc. -- Co-Investigator
3. Efficacy and Safety of Domperidone in Patients with Diabetic Gastroparesis
Janssen Research -- Principal Investigator
4. Treatment of Infected Diabetic Foot Ulcers
Magainin Pharmaceuticals, Inc. -- Co-Investigator
5. An Insulin Sensitizer in the treatment of NIDDM Patients Requiring Insulin, Phase I & Phase II
Parke-Davis Pharmaceutical Research -- Principal Investigator
6. Protect (Precose) Study in NIDDM
Bayer Pharmaceuticals -- Co-Investigator
7. Feminine Hygiene Study
International Pharmaceutical Research -- Sub-Investigator
8. Human X-14 Insulin Study Type I DM
Novo Nordisk Pharmaceuticals -- Principal Investigator
9. IGF-I in Type I DM
Genentech, Inc. -- Sub-Investigator

PREVIOUS RESEARCH PROJECTS (Continued):

10. Intravitreal injection of Hyaluronidase in Vitreal Hemorrhage
Advanced Corneal Systems, Inc. -- Sub-Investigator
11. Type II DM with Renal Impairment using Voglibose
Takeda America, Inc. -- Sub-Investigator
12. Open-Label Pramlintide in the Treatment in Type I DM
Amylin Pharmaceuticals -- Principal Investigator
13. Postmenopausal Women with Established Osteoporosis-Related Vertebral

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 13

Deformities

- Proctor & Gamble -- Principal Investigator
14. Topical Nitroglycerin Cream for the Treatment of Erectile Dysfunction
International Medcial Innovations, Inc. -- Sub-Investigator
 15. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 9 Week Study of Omapatrilat in the Treatment of Mild to Moderate Hypertension
Bristol-Myers Squibb -- Sub-Investigator
 16. A Randomized, Placebo-Controlled, Parallel-Group Study of CS-866 with Long-Term Safety Evaluation in Patients with Essential Hypertension
Sankyo USA -- Sub-Investigator
 17. Evaluating Metformin HCl Vs. Glyburide in Subjects With Type II Diabetes Mellitus Controlled On Sulfonylurea Monotherapy
Bristol-Myers Squibb -- Principal Investigator
 18. An Open-Label, Community-Based Clinical Practice Study of Niaspan in Patients with Hyperlipidemia
Kos Pharmaceuticals -- Sub-Investigator
 19. A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Prospectively Evaluate the Post-Prandial Glucose Excursion, the Daytime Glucose and Insulin Profiles, Safety, and Tolerability of a Fixed Dose of SDZ DJN 608, A Forced Titrated Dose of Glyburide, and Placebo in Subjects with NIDDM on Diet Alone
Novartis Pharmaceuticals -- Sub-Investigator
 20. A Comparison of Echocardiographic Findings in Patients Treated with Redux
Interneuron Pharmaceuticals, Inc.—Sub-Investigator
 21. TRICOR U.S. Multicenter Physician Experience Trial
Abbott Laboratories Inc.—Principal Investigator
 22. Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide on Glycemic Control as Determined by Glycated Hemoglobin in Patients with Type II Diabetes Mellitus
Amylin Pharmaceuticals -- Sub-Investigator
 23. Open-Label Long-Term Study of the Antihypertensive Activity and Safety of Omapatrilat, a Dual Metalloprotease Inhibitor, in the Treatment of Hypertension
Bristol-Myers Squibb -- Sub-Investigator
 24. Reach-Rezulin Achieves Glycemic Control; A Multicenter, 24-week, Open-Label, Dose-Escalation Trial of Rezulin in Combination with Insulin or Sulfonylurea in Type II Diabetes Mellitus Patients
Parke-Davis -- Sub-Investigator

PREVIOUS RESEARCH PROJECTS (Continued):

25. Safety and Efficacy of Fixed Combination Metformin/Glyburide Products as First Line Therapy in Patients with Type II Diabetes Mellitus who Have Inadequate Glycemic Control with Diet and Exercise
Bristol-Myers Squibb -- Principal Investigator
26. A Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide on Glycemic Control as Determined by Glycated Hemoglobin in Patients with Type I Diabetes Mellitus
Amylin Pharmaceuticals -- Sub-Investigator

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 14

27. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 18 Month Study to Assess the Safety and Efficacy of Meridia 20 mg
Knoll Pharmaceuticals -- Co-Investigator
28. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of the Efficacy and Safety of Metformin Hydrochloride for the Treatment of Adolescents with Type 2 Diabetes Mellitus
Bristol-Myers Squibb -- Sub-Investigator
29. Efficacy and Safety of Inhaled Human Insulin Compared to Subcutaneous Human Insulin in an Intensive Insulin Regimen for Subjects with Type 1 DM
Pfizer, Inc.—Sub-Investigator
30. Efficacy and Safety of Inhaled Human Insulin Therapy in Subjects with Type 2 DM Not Well-Controlled with Combination Oral Agents
Pfizer, Inc. -- Sub-Investigator
31. Double- Blind, Placebo- Controlled, Four-Week Study of the Safety and Efficacy of CP-386,296 in Subjects with Type 2 DM
Pfizer Inc. – Sub-Investigator
32. Glipizide GITZ Study in Usual Care Setting
Pfizer, Inc – Sub-Investigator
33. The Effect of PNU-182716 on HbA1c Levels in Type 2 Diabetic Patients, a Double-Blind, Placebo-Controlled, Randomized, Multicenter Dose-Finding and Frequency Study
Pharmacia & UpJohn – Sun-Investigator
34. A Randomized, Double-Blind, Parallel- Group, Pilot Study of 3 Months Treatment with Oral GI262570 7.5 mg Once Daily, Pioglitazone 45 mg Once Daily, and Rosiglitazone 4 mg Twice Daily in Subjects with Type 2 DM
Glaxo Wellcome—Sub-Investigator
35. Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Noninsulin Dependent Diabetes Mellitus and Nephropathy
Merck & Company -- Co- Investigator
36. Efficacy and Safety of Inhaled Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus not Optimally Controlled with Diet and Exercise
Pfizer, Inc.—Sub-Investigator
37. Insulin Lispro Low Mixture Plus Metformin Compared to NPH Insulin Plus Metformin in Subjects with Type 2 DM
Eli Lilly and Company – Sub-Investigator

CURRENT RESEARCH PROJECTS :

1. A Triple-Blind, Parallel Study to Investigate the Effect of Losartan versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy
Merck & Company -- Co- Investigator
2. The Hypopituitary Control and Complications Study with Humatrope
Eli Lilly and Company -- Sub-Investigator

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 15

3. Long Term Safety of Inhaled Insulin in Subjects with Type 1 or Type 2 DM
Pfizer, Inc -- Sub-Investigator
4. Double-Blind, Randomized Study of the Safety and Efficacy of a Combination of Insulin and 30 mg of Actos vs. a Combination of Insulin and 45 mg of Actos in the Treatment Type 2 DM
Takeda America -- Sub- Investigator
5. A Randomized, Double-Blind, Parallel- Group, Placebo-Controlled Clinical Evaluation of GI262570 Sodium Tablets as a Monotherapy for 26 weeks in Subjects with Type 2 DM
Glaxo Wellcome—Sub-Investigator
6. A Randomized, Double-Blind, Parallel- Group, Clinical Evaluation of GI262570 Sodium Tablets in Combination with Metformin for 26 weeks in Subjects with Type 2 DM
Glaxo Wellcome—Sub-Investigator
7. A Double-Blind, Randomized Comparison Study of the Safety and Efficacy of the Addition of Pioglitazone or Placebo in Reducing or Eliminating Insulin Requirement in Subjects Controlled on Insulin and Metformin Who Have Previously Failed Combination Oral Therapy
Takeda Pharmaceuticals America—Sub-Investigator
8. A Double-Blind, Randomized Comparison Study of the Long Term (2 yr) Safety and Efficacy of Pioglitazone or Glyburide in Subjects with Type 2 DM Naïve to Pharmacologic Therapy
Takeda Pharmaceuticals America—Sub-Investigator
9. Randomized, Multicenter, Double-Blind, Placebo-Controlled trial with Two Parallel Groups to Measure the Efficacy of 12 Weeks Treatment with 120 mg of Nateglinide vs Placebo in Treatment of Naïve Older Seniors with Type 2 DM
Novartis Pharmaceuticals -- Sub-Investigator
10. Multicenter, Randomized, Double-Blind Trial Comparing the Safety and Efficacy of Metformin/Glyburide to Pioglitazone in Patients with Type 2 DM
Bristol-Myers Squibb -- Sub-Investigator
11. Double-Blind Randomized Study to Evaluate the Effects of Fixed Combination Metformin/Glipizide in Patients with Type 2 DM
Bristol-Myers Squibb – Sub-Investigator

CURRENT RESEARCH PROJECTS (Continued):

12. Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect on Glucose Control of AC2993 in Subjects with Type 2 DM
Amylin Pharmaceuticals -- Sub-Investigator
13. 18 Month, Double-Blind Phase 3 Trial with a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone in Women with Postmenopausal Osteoporosis
NPS Allelix Corporation – Sub-Investigator
14. Randomized, Open Label, Crossover Trial in Insulin Requiring Diabetic Patients, Comparing the Injections with BiaSp 30/MS216 Disposable Pen Device and Injections with BiaSp 30/vial and Syringe

Curriculum Vitae

Paul S. Jellinger, M.D., M.A.C.E.

Page 16

- Novo Nordisk Pharmaceuticals, Inc. – Sub-Investigator
15. NNC61-0029 in Type 2 DM Hypertriglyceridemic Patients: Double-Blind, Parallel, Placebo-Controlled with an Open Pioglitazone Arm
- Novo Nordisk Pharmaceuticals, Inc. – Sub-Investigator
16. Randomized, Double-Blind, Parallel-Group, Dose-Ranging Study to Assess the Efficacy and Safety of GI262570 Administered as a Daily Dose in Subjects with Type 2 DM
- Glaxo Wellcome, Inc. – Sub-Investigator
17. Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Treatment with Simvastatin in TZD Treated Type 2 DM Patients
- Merck & Co., Inc. – Sub-Investigator
18. Efficacy, Dose-Ranging and Safety for RWJ-241947 in Type 2 DM Patients Inadequately Controlled on Diet, Metformin, or Sulfonylurea: A Phase 2b Trial
RW Johnson PRI – Sub-Investigator